Raymond Lai

发表

University of Alberta “OMICs” Conference, June 17, 2013: Conference Program and Abstracts

Fang Wu, David S. Wishart, Sambasivarao Damaraju, 2013 .

Immunohistochemistry for human concentrative nucleoside transporter 3 protein predicts fludarabine sensitivity in chronic lymphocytic leukemia

Sunita Ghosh, Raymond Lai, John R Mackey, 2008, Modern Pathology.

STAT3 upregulates the protein expression and transcriptional activity of β-catenin in breast cancer.

John Mackey, Raymond Lai, J. Mackey, 2010, International journal of clinical and experimental pathology.

Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells

Ping Shi, Raymond Lai, Guillermo Garcia-Manero, 2009, Journal of cellular and molecular medicine.

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

Adam P Dicker, Raymond Lai, John R Mackey, 2009, Gastroenterology.

Sox2 suppresses the invasiveness of breast cancer cells via a mechanism that is dependent on Twist1 and the status of Sox2 transcription activity

Peng Wang, Gilbert Bigras, Karen Jung, 2013, BMC Cancer.

A two-stage association study identifies methyl-CpG-binding domain protein 2 gene polymorphisms as candidates for breast cancer susceptibility

Sambasivarao Damaraju, Yadav Sapkota, Raymond Lai, 2012, European Journal of Human Genetics.

The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma

John R. Mackey, Carol Cass, Raymond Lai, 2004, Clinical Cancer Research.

miR-200b suppresses invasiveness and modulates the cytoskeletal and adhesive machinery in esophageal squamous cell carcinoma cells via targeting Kindlin-2.

Kai Zhang, Bo Chen, Raymond Lai, 2014, Carcinogenesis.

Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer

Carol Cass, Raymond Lai, Sergio Rizzo, 2010, Journal of cellular physiology.

The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma

Tony Reiman, Raymond Lai, Linda M Pilarski, 2008, British journal of haematology.

Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach

Zhong Zheng, Yun Yen, Chandan Guha, 2016, Pancreas.

Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma

John R. Mackey, Isabelle Salmon, Marc Peeters, 2009, Clinical Cancer Research.